Although current cancer immunotherapies that target PD-1/PD-L1 immune checkpoint to
reinvigorate exhausted T cells have achieved impressive clinical outcomes, only a small …

To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to
the lack of early diagnosis and personalized treatment strategies. In this context, the …

Purpose: Limited effective treatments are currently available for central nervous system
(CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to …

The autosomal recessive genome instability disorder Ataxia–telangiectasia, caused by
mutations in ATM kinase, is characterized by the progressive loss of cerebellar neurons. We …

Cancer diagnoses have been increasing worldwide, and solid tumors are among the
leading contributors to patient mortality, creating an enormous burden on the global …

Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

Diffuse intrinsic pontine glioma (DIPG) kills more children than any other type of brain tumor.
Despite clinical trials testing many chemotherapeutic agents, palliative radiotherapy remains …

Immunotherapy has revolutionized the landscape in clinical tumor therapy, although the
response rates in “cold” tumors are relatively low owing to the complex tumor …

Personalized medicine and therapies represent the goal of modern medicine, as drug
discovery strives to move away from one-cure-for-all and makes use of the various targets …

Glioblastoma (GBM), the most aggressive primary brain tumor, has a dismal prognosis.
Despite our growing knowledge of genomic and epigenomic alterations in GBM, standard …